GIP receptor antagonist and GLP-1 receptor agonist
Mari sc
MARI_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.41 (0.01 to 27.12) | 0.69 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.44 (0.01 to 31.24) | 0.74 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.17 (1.89 to 65.90) | 0.22 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 26.55 (3.58 to 534) | 0.13 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 6.03 (0.56 to 155) | 0.22 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.98 (0.30 to 123) | 0.33 |